anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
People with a substance use disorder (SUD) have shortened lifespans due to complications from their substance use and challenges engaging with traditional health care settings and institutions. This impact on life expectancy is especially prominent in patients with co-occurring SUDs and cancer, and often has a much worse prognosis from the cancer than a similar patient without a SUD. Palliative care teams are experts in serious illness communication and symptom management and have become increasingly embedded in the routine care of patients with cancer. We argue that the skill set of palliative care teams is uniquely suited for addressing the needs of this oft marginalized group. We provide a comprehensive review of tools for addressing these needs, including medications that can both treat pain and opioid use disorder (OUD), and highlight psychosocial approaches to treating patients with OUD and cancer in a way that is respectful and effective. Using a trauma informed framework, we focus on the application of harm reduction principles from addiction medicine and the principles of clear communication, accompaniment, and emotional presence from palliative care to maximize support. We also focus on ways to reduce stigma in the delivery of care, by providing language that reduces barriers and increases patient engagement. Finally, we describe a clinic embedded within our institution's cancer center which aims to serve patients with cancer and SUDs, built on the framework of harm reduction, accompaniment and trauma informed care (TIC). Overall, we aim to provide context for addressing the common challenges that arise with patients with cancer and OUD, including the direct impact of psychosocial stress on substance use and cancer treatment, delays in disease directed treatment that can potentially impact further treatment options and outcomes, challenging pain management due to greater opioid debt, and potential loss of primary coping mechanism through substance use in the face of potential terminal diagnosis.
Placebo combined with SOX (S-1/oxaliplatin) regimen preoperatively used 3 cycles(stop placebo and S-1/oxaliplatin after 3 cycles and evaluate tumor staging)→ radical surgery (D2) →Postoperative selection of continued medication or cessation of treatment will base on the patient's pathological reports. Surgery should be performed within 3-6 weeks after 3 cycles of preoperative neoadjuvant therapy.
An antibacterial and antiviral material composition is composed of two structural bodies. The first structural body is a base material, which is made of a basic material including but not limited to fibers, yarns and fabrics. The second structural body is a multi-metal nanostructure, which is a structure in which two or more metal atoms are combined into a nanoparticle form by physical means such as stacking or coating. The two structural bodies are physically mixed to form a material composition with an antibacterial and antiviral mechanism. Through an electronic network formed on a surface of this material composition, the free atoms of multi-metal nanoparticles adsorb hydrogen or oxygen molecules in the air and hydrogen peroxide is generated on an outer surface of the material composition, thereby generating free radical protective layer with strong antibacterial and antiviral properties. In this way, a nano armour is formed as a whole such that viruses and bacteria can not survive and replicate on the material composition, thereby achieving the optimal antibacterial and antiviral effect.
This study aimed to establish a predictive model for the risk of post-thoracic endovascular aortic repair (TEVAR) post-implantation syndrome (PIS) in type B aortic dissection (TBAD) patients, assisting clinical physicians in early risk stratification and decision management for high-risk PIS patients. This study retrospectively analyzed the clinical data of 547 consecutive TBAD patients who underwent TEVAR treatment at our hospital. Feature variables were selected through LASSO regression and logistic regression analysis to construct a nomogram predictive model, and the model's performance was evaluated. The optimal cutoff value for the PIS risk nomogram score was calculated through receiver operating characteristic (ROC) curve analysis, further dividing patients into high-risk group (HRG) and low-risk group (LRG), and comparing the short to midterm postoperative outcomes between the two groups. In the end, a total of 158 cases (28.9%) experienced PIS. Through LASSO regression analysis and multivariable logistic regression analysis, variables including age, emergency surgery, operative time, contrast medium volume, and number of main prosthesis stents were selected to construct the nomogram predictive model. The model achieved an area under the curve (AUC) of 0.86 in the training set and 0.82 in the test set. Results from calibration curve, decision curve analysis (DCA) and clinical impact curve (CIC) demonstrated that the predictive model exhibited good performance and clinical utility. Furthermore, after comparing the postoperative outcomes of HRG and LRG patients, we found that the incidence of postoperative PIS significantly increased in HRG patients. The duration of ICU stay and mechanical assistance time was prolonged, and the incidence of postoperative type II entry flow and acute kidney injury (AKI) was higher. The risk of aortic-related adverse events (ARAEs) and major adverse events (MAEs) at the first and twelfth months of follow-up also significantly increased. However, there was no significant difference in the mortality rate during hospitalization. This study established a nomogram model for predicting the risk of PIS in patients with TBAD undergoing TEVAR. It serves as a practical tool to assist clinicians in early risk stratification and decision-making management for patients.
The Cannabis Harm-reducing App for Managing Practices Safely (CHAMPS) is a brief harm reduction e-intervention based on the principles of motivational interviewing and harm reduction approaches. This e-intervention will be completed by the participant using a smart phone. There will be a total of six individual sessions each lasting 15-20 min. There will be one booster session offered at 4 weeks post-intervention to review goal setting, evaluate motivation around changing cannabis use practices. This e-intervention will be administered adjunctively to psychosis early intervention services (EIS).
The primary endpoints of this pilot trial will be the safety and feasibility of administering ipilimumab with Adoptive Cell Therapy (ACT) using TIL. The data analysis will mainly be descriptive. All study results will be preliminary and of exploratory in nature due to the pilot status and small sample size of the trial. Feasibility is defined as the ability to deliver at least 50% (i.e., two out of four) of the planned doses of ipilimumab and successfully treat at least 60% (i.e., ≥ 6/10) of the patients with TIL. All participants will be evaluable for toxicity from the time of their first protocol treatment. Toxicity will be reported by type and severity according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) version 4.
Cabozantinib 60 mg given orally daily for 28 days (4 weeks) each cycle. Participants were treated until disease progression, unacceptable toxicity or withdrawal for other reasons.
Participants received setmelanotide once daily (QD) via SC injection for 16 weeks. All participants initiated treatment with setmelanotide (starting dose being age dependent) and dose escalated up to a maximum dose of 3.0 milligrams (mg) QD.
A frenum is a fibrous band of tissue attached to the bone of the maxilla and mandible, it is frequently superficial to the muscle attachments. There are different types of frena in a normal oral cavity, most notably the maxillary labial frenum, the mandibular labial frenum, the buccal frenum and the lingual frenum. The primary function of frenum is to provide stability of the upper and lower lip. Labial frenal attachments are thin folds of mucous membrane with enclosed muscle fibers originating from orbicularis oris muscle of the upper lip that attaches at the lips to the alveolar mucosa and underlying periosteum on the middle part of the upper lip between the upper central incisors. The labial frenum has unpredictable variation in reference to size, shape, and position during different time periods of growth and development. During the growth period, it is of less clinical importance as it has the ability to decrease in size. At a younger age frenum is generally wide and thick, with time it becomes thin and small .

Abnormal frenum attachment can lead to distension of the gingival sulcus because of frenal pull causing severe periodontal pockets as there is increase plaque accumulation and gingival recession may be caused by the frenum when attached too closely to the gingival margin. It may even affect denture fit or retention. Abnormal labial frenum has also been associated with various syndromes like Ehlers-Danlos syndrome. There are different types and variations of the labial frenum, for this the frenum assessment during oral examination is important in order to avoid misdiagnosis of normal variations as abnormal frenum.
The researcher will apply pressure to the P6 acupressure point on both wrists for approximately 5 minutes at the same time as chemotherapy. He will also have the patient or a relative repeat the method and do it at home three times a day before meals for 5 days.
Platelets play a critical role as circulating cells in the human body and contribute to essential physiological processes such as blood clotting, hemostasis, vascular repair, and thrombus formation. Currently, platelets are extensively employed in the development of innovative biomimetic drug delivery systems, offering significant enhancements in circulation time, biocompatibility, and targeted delivery efficiency compared to conventional drug delivery approaches. Leveraging the unique physiological functions of platelets, these platelet-derived drug delivery systems (DDSs) hold great promise for the treatment of diverse diseases, including cancer, cardiovascular diseases, infectious diseases, wound healing and other diseases. This review primarily focuses on the design and characteristics of existing platelet-derived DDSs, including their preparation and characterization methods. Furthermore, this review comprehensively outlines the applications of these materials across various diseases, offering a holistic understanding of their therapeutic potential. This study aimed to provide a comprehensive overview of the potential value of these materials in clinical treatment, serving as a valuable reference for the advancement of novel platelet-derived DDSs and their broader utilization in the field of disease treatment.
Premature Closure of Fetal Ductus Arteriosus

Avoid use of NSAIDs, including ZIPSOR, in pregnant women at about 30 weeks gestation and later. NSAIDs, including ZIPSOR, increase the risk of premature closure of the fetal ductus arteriosus at approximately this gestational age.

Oligohydramnios/Neonatal Renal Impairment

Use of NSAIDs, including ZIPSOR, at about 20 weeks gestation or later in pregnancy may cause fetal renal dysfunction leading to oligohydramnios and, in some cases, neonatal renal impairment. These adverse outcomes are seen, on average, after days to weeks of treatment, although oligohydramnios has been infrequently reported as soon as 48 hours after NSAID initiation. Oligohydramnios is often, but not always, reversible with treatment discontinuation. Complications of prolonged oligohydramnios may, for example, include limb contractures and delayed lung maturation. In some postmarketing cases of impaired neonatal renal function, invasive procedures such as exchange transfusion or dialysis were required.

If NSAID treatment is necessary between about 20 weeks and 30 weeks gestation, limit ZIPSOR use to the lowest effective dose and shortest duration possible. Consider ultrasound monitoring of amniotic fluid if ZIPSOR treatment extends beyond 48 hours. Discontinue ZIPSOR if oligohydramnios occurs and follow up according to clinical practice [see Use in Specific Populations (8.1)].
The present invention relates to an anti-SARS virus medicament of the rare earth heteropoly acid salt (blue) class and a synthetic method thereof, which belongs to a chemosynthesis medicament and a synthetic method thereof. The general formula of the anti-SARS virus medicament is Ax(H2O)x [AyLnz(H2O)2xClqXjM[12-m]M'mO40]. nOg, and the anti-SARS virus medicament is a rare earth polyacid compound in a Keggin structure. The method for preparing the medicament comprises the technical processes: sodium tungstate dihydrate chloride dihydrate and a compound containing transition elements in the IIIA-VA family or the d district are dissolved in distilled water; after titanium tetrachloride is dropped, distillation return, filtration and recrystallization are carried out to be dissolved in water; a reducing agent is added to be stirred, etc. The nonpoisonous concentration to VeroE6 cells in the anti-SARS virus medicament is 100 mug/ml, the concentration has the effect of complete suppression to SARS viruses. The present invention has the advantages of high activity for suppressing SARS viruses, low toxicity and low price (one patient with SARS needs about 100 yuan).
Subjects will receive CSFD and elevation of MAP. Treatments will be 120 hours (5 days) from time treatment is initiated (time 0), and within 24 hours of time of injury. Initiation of CSFD will occur after decompression (during surgery) with a target ITP of 10 mmHg. MAP elevation (norepinephrine drip; goal 100-110 mmHg) will start during surgery, simultaneously with CSFD. 10 mL of CSF will be collected daily for routine lab testing. Post-surgery subjects will be transferred to an intensive care unit (ICU) for duration of treatment or longer if clinically indicated. Target MAP will be sustained within 100-110 mmHg for 5 days. Norepinephrine drip will be used to maintain MAP goal. Subjects will receive other treatment per standard of care at the participating investigational sites.
<P>PROBLEM TO BE SOLVED: To provide an image transfer device (a gateway) for accurately and speedily transmitting/receiving information between a plurality of subject information processing terminals and a medical image processor (a modality).  <P>SOLUTION: IP addresses of MWM servers 1, ..., 1 are previously registered in the gateway 2, and patient information is obtained and saved from the MWM servers via a LAN 5 by using the IP addresses. Then, applicable patient information is transmitted to the modality 3 based on the request for transmitting the patient information from the modality 3. After that, image information including the patient information from the modality 3 is received and transferred to an image server 4. If the modality 3 is moved from an examination room A to an examination room B and set there, the operation can be performed without changing setting or operation on the modality 3 side. Accordingly, information can be accurately and speedily transmitted/received between the MWM servers 1, ..., 1 and the modality 3.  <P>COPYRIGHT: (C)2007,JPO&INPIT
PURPOSE:To provide the subject food effectively acting on various symptoms developed due to malbloodstream, containing, as active ingredient, lipids on the periphery of the internal organs of Pelamis platurus (a kind of sea serpent belonging to Hydrophiidae). CONSTITUTION:The head and tail of Pelamis platurus are removed, and the internal organ bag with lipids stuck to its periphery is taken out and thoroughly washed with water to wash the blood off. Thence, the bag, in a pressurized state, is heated in water for ca.2hr to completely separate the lipids from the bag and the pale yellow lipids in the supernatant is collected. The lipids thus taken is mixed with various food stocks to obtain the objective blood stream- improving food in an known form. Or, the lipids is formulated with an edible fatty oil such as safflower oil, vitamin E, and lecithin followed by encapsulation using e.g. gelatin. The lipids is rich in highly unsaturated fatty acids such as docosahexaenoic acid and docosapentaenoic acid and has high blood stream- improving activity, thus promising possible efficacy for such symptoms as to have not been improved even if vitamin E is taken, also being high in safety.
Grade III cervical mobilization technique as described by Maitland. Applied to left C5/6 Segment.
The present invention is a novel class of compounds useful in thermally-responsive record material of the type comprising a substrate having provided thereon in substantially contiguous relationship an electron donating dye precursor, and an acidic developer material. The novel compound of the invention is a compound of the formula (I), wherein P is selected from (II) and (III) wherein R~1? is selected from hydrogen, alkoxy, and aralkoxy;  wherein R~2? is aralkoxyalkoxy when P is phenyl, and R~2? is selected from aralkoxyalkoxy or alkoxyalkoxy when P is naphthyl. Said alkyl moieties are each independently from one to eight carbons, said aryl moieties each independently being unsubstituted or substituted by alkyl (C~1?-C~8?), alkoxy (C~1?-C~8?) or halogen. The compounds of the invention enable manufacture of thermally responsive record material of the invention having the unexpected and remarkable properties of enhanced image intensity or density, and/or improved thermal response. The compounds of the invention also find use in diverse applications such as emolients and softening agents for creams, lots and cosmetics.
Patients will be routinely prescribed medications for pain control and are referred for physical therapy on an out-patient basis in different sites or an in-patient basis in specialized rehabilitation centers following lumbar spinal fusion surgery, depending on the needs. Typically, a full rehabilitation regime starts 2-3 weeks after surgery. Usual programs involve active spinal mobilization aimed at gradually improving the range of motion, exercises to strengthen spinal deep muscles, and segmentary stretching involving the lower limb and back muscles, together with manual therapy. The patients are also given walking exercises and trained in how to change position.
Participants will receive 2 mg of env (A,B,C,A/E)/gag (C) DNA vaccine and placebo at Day 0 and Months 1 and 3. Participants will receive 400 mcg of gp120 (A,B,C,A/E) protein vaccine admixed with GLA-SE adjuvant and a placebo vaccine at Months 6 and 8.
The microemulsion is of the type containing a water-soluble phase and a lipid phase, comprising, in the form of a mixture:  . at least one water-soluble phase,  . at least one lipid phase,  . at least one surfactant,  . at least one cosurfactant,  characterised: - in that the surfactant is a mixed ester of glycerol and polyethylene glycol and represents at least ten per cent (10%) by weight of the mixture; - in that the cosurfactant is an ester of polyglycerol and a liquid fatty acid, which is in the mixture in a smaller proportion than that of the surfactant and represents at least five per cent (5%) by weight of the mixture; - and in that the lipid compound possesses a hydrophilic/lipophilic balance not exceeding three. Use envisaged: pharmaceutical excipients or cosmetological bases.
Diarrhea is the second leading cause of death for children around the world. This is true despite the fact that nearly all such deaths could be prevented with a simple and inexpensive solution: oral rehydration salts (ORS). Private health care providers, who treat the majority of childhood illness in low- and middle-income countries (LMICs), are particularly unlikely to dispense ORS to children with diarrhea. Instead, providers often dispense antibiotics inappropriately. Recognizing this significant challenge, several international organizations (including USAID) have invested heavily in trying to increase ORS dispensing in the private sector. In the absence of evidence on why ORS is so inconsistently dispensed by private providers, however, several interventions to promote private sector ORS dispensing have been ineffective. Clearly, a critical and urgent next step is to examine the key drivers of underprescription of ORS and overprescription of antibiotics in the private sector in order to inform efforts to improve diarrhea care. In this study, we examine several leading explanations for poor quality of care for child diarrhea in the private sector. First, patient preferences for ORS alternatives (e.g., an antibiotic) could be driving underprescription of ORS. We will identify the causal effect of patient preferences (Aim 1) by having anonymous standardized patients (SPs) pose as caretakers of children with diarrhea and express different (randomly assigned) preferences for treatment (ask for ORS, ask for antibiotics, or let provider decide). Second, private providers could be responding to financial incentives to sell more profitable alternatives to ORS (e.g., an antibiotic). To estimate the causal effect of financial incentives (Aim 2), we will instruct a subset of SPs to inform providers that they can get discounted treatments at a relative's drug shop. This eliminates the provider's financial incentive to recommend a given treatment and allows us to estimate the effect of such incentives. Finally, private providers might not directly distribute ORS or could have frequent stock-outs. To estimate the causal effect of stock-outs (Aim 3), we will randomly assign half of the providers to receive a three-month supply of ORS. This generates exogenous variation in stock outs and thus enables us to isolate the causal effect of stock outs on ORS and antibiotic prescribing. Combining, (a) causal estimates of the impact of each factor on prescribing, and (b) population estimates of the prevalence of each factor, will allow us to estimate the population level impact of implementing interventions that address each factor (Aim 4). This study will provide the most comprehensive evidence to date on why one of the most important health technologies in history is often not prescribed. The results will inform the design of interventions aimed at increasing ORS dispensing and reducing antibiotic dispensing. If such interventions are targeted appropriately, millions of young lives could be saved.
Methods, systems, and computer program products for assigning times of administration to patient medications are described. A GUI is displayed within a display associated with a pharmaceutical dispensing system. The GUI includes a one day time scale for assigning a time of administration for the medication. One or more daily times of administration for the medication are assigned in response to user input via the one day time scale. A dose of the medication is packaged in each of a respective plurality of pouches according to the assigned daily times of administration via the pharmaceutical dispensing system. The one day time scale may include a time line representative of a twenty-four hour period and one or more time indicators that are positionable by a user. The one day time scale may include a plurality of food consumption times, each selectable by a user for assigning a time of administration.
XOSPATA has been associated with prolonged cardiac ventricular repolarization (QT interval). Of the 317 patients with a post-baseline QTc measurement on treatment with XOSPATA in the clinical trial, 1% were found to have a QTc interval greater than 500 msec and 7% of patients had an increase from baseline QTc greater than 60 msec. Perform electrocardiogram (ECG) prior to initiation of treatment with gilteritinib, on days 8 and 15 of cycle 1, and prior to the start of the next two subsequent cycles. Interrupt and reduce XOSPATA dosage in patients who have a QTcF >500 msec [see Dosage and Administration (2.3), Adverse Reactions (6.1) and Clinical Pharmacology (12.2)].

Hypokalemia or hypomagnesemia may increase the QT prolongation risk. Correct hypokalemia or hypomagnesemia prior to and during XOSPATA administration.